Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01543542 : A Phase II Multi-institutional Study Assessing Simultaneous In-field Boost Helical Tomotherapy for 1-3 Brain Metastases
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Histological diagnosis of primary cancer

- Contrast enhanced MRI demonstrating 1-3 metastases within 6 weeks of enrollment

- Age greater than or equal to 18

- Karnofsky performance status greater than or equal to 70

- Patient available for subsequent follow-up appointments and testing as well as
health-related quality of life questionnaires

- Anticipated survival (independent of the brain metastases) greater than 3 months

- Patient informed consent obtained

- Metastatic suitable for synchronous boost

- Extracranial disease controlled or to be treated

Exclusion Criteria:

- Underlying medical condition precluding adequate follow-up

- Prior cranial radiotherapy

- Concurrent cytotoxic chemotherapy
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557